EA036671B1 - Способ лечения и диагностики метастатического колоректального рака на основании уровня vegf-a - Google Patents
Способ лечения и диагностики метастатического колоректального рака на основании уровня vegf-a Download PDFInfo
- Publication number
- EA036671B1 EA036671B1 EA201790549A EA201790549A EA036671B1 EA 036671 B1 EA036671 B1 EA 036671B1 EA 201790549 A EA201790549 A EA 201790549A EA 201790549 A EA201790549 A EA 201790549A EA 036671 B1 EA036671 B1 EA 036671B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- vegf
- level
- patient
- patients
- aflibercept
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051091P | 2014-09-16 | 2014-09-16 | |
| US201562099630P | 2015-01-05 | 2015-01-05 | |
| PCT/US2015/049279 WO2016044041A1 (en) | 2014-09-16 | 2015-09-10 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201790549A1 EA201790549A1 (ru) | 2017-07-31 |
| EA036671B1 true EA036671B1 (ru) | 2020-12-07 |
Family
ID=54207741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790549A EA036671B1 (ru) | 2014-09-16 | 2015-09-10 | Способ лечения и диагностики метастатического колоректального рака на основании уровня vegf-a |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10525104B2 (https=) |
| EP (1) | EP3194974B1 (https=) |
| JP (1) | JP6692358B2 (https=) |
| KR (1) | KR102471057B1 (https=) |
| CN (1) | CN107076749B (https=) |
| AU (1) | AU2015318207B2 (https=) |
| CA (1) | CA2960890A1 (https=) |
| EA (1) | EA036671B1 (https=) |
| IL (1) | IL250905B (https=) |
| MX (1) | MX382673B (https=) |
| WO (1) | WO2016044041A1 (https=) |
| ZA (1) | ZA201701664B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1216765A1 (zh) | 2013-03-14 | 2016-12-02 | 奥特拉西斯公司 | 使用所测分析物改进疾病诊断的方法 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| RU2018127709A (ru) | 2016-01-22 | 2020-02-25 | Отрэйсис, Инк. | Системы и способы улучшения диагностики заболеваний |
| KR20190131538A (ko) * | 2017-03-31 | 2019-11-26 | 가부시키가이샤 히로츠 바이오 사이언스 | 암 환자의 치료 효과의 예측 및/또는 재발 모니터링 |
| FI3743091T3 (fi) | 2018-01-26 | 2025-01-03 | Univ California | Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| WO2020165483A1 (es) * | 2019-02-15 | 2020-08-20 | Universidad de Córdoba | Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos |
| US20210012899A1 (en) * | 2019-07-13 | 2021-01-14 | Otraces, Inc. | Diagnosis for various diseases using tumor microenvironment active proteins |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021076852A1 (en) * | 2019-10-17 | 2021-04-22 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
| WO2021108255A1 (en) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Long-acting vegf inhibitors for intraocular neovascularization |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CN101283280A (zh) * | 2005-08-18 | 2008-10-08 | Zadec私人有限公司 | 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途 |
| US20110070186A1 (en) * | 2009-08-14 | 2011-03-24 | Allergan, Inc. | Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases |
| AU2011208805A1 (en) * | 2010-01-19 | 2012-06-21 | F. Hoffman-La Roche Ag | Tumor tissue based biomarkers for bevacizumab combination therapies |
| EP2848939A1 (en) * | 2010-07-19 | 2015-03-18 | F. Hoffmann-La Roche AG | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
-
2015
- 2015-09-10 AU AU2015318207A patent/AU2015318207B2/en active Active
- 2015-09-10 CA CA2960890A patent/CA2960890A1/en active Pending
- 2015-09-10 US US15/509,461 patent/US10525104B2/en active Active
- 2015-09-10 JP JP2017533704A patent/JP6692358B2/ja active Active
- 2015-09-10 WO PCT/US2015/049279 patent/WO2016044041A1/en not_active Ceased
- 2015-09-10 CN CN201580049558.1A patent/CN107076749B/zh active Active
- 2015-09-10 EP EP15771819.8A patent/EP3194974B1/en active Active
- 2015-09-10 EA EA201790549A patent/EA036671B1/ru unknown
- 2015-09-10 MX MX2017003387A patent/MX382673B/es unknown
- 2015-09-10 KR KR1020177007326A patent/KR102471057B1/ko active Active
-
2017
- 2017-03-02 IL IL250905A patent/IL250905B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01664A patent/ZA201701664B/en unknown
-
2019
- 2019-11-21 US US16/690,459 patent/US11439683B2/en active Active
Non-Patent Citations (5)
| Title |
|---|
| HIDETOSHI HAYASHI, TOKUZO ARAO, KAZUKO MATSUMOTO, HIDEHARU KIMURA, YOSUKE TOGASHI, YOSHINORI HIRASHIMA, YOSUKE HORITA, SATORU IWAS: "Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma", ONCOTARGET, UNITED STATES, 15 May 2014 (2014-05-15), United States, pages 2588, XP055163018, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/24809949> DOI: 10.18632/oncotarget.1811 * |
| J M J�RGENSMEIER, H-J SCHMOLL, J D ROBERTSON, L BROOKS, M TABOADA, S R MORGAN, D WILSON, P M HOFF: "Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 108, no. 6, 2 April 2013 (2013-04-02), GB, pages 1316 - 1323, XP055230575, ISSN: 0007-0920, DOI: 10.1038/bjc.2013.79 * |
| J. L. SPRATLIN, COHEN R. B., EADENS M., GORE L., CAMIDGE D. R., DIAB S., LEONG S., O'BRYANT C., CHOW L. Q.M., SERKOVA N. J., MEROP: "Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 28, no. 5, 10 February 2010 (2010-02-10), US, pages 780 - 787, XP055230184, ISSN: 0732-183X, DOI: 10.1200/JCO.2009.23.7537 * |
| P. S. HEGDE, A. M. JUBB, D. CHEN, N. F. LI, Y. G. MENG, C. BERNAARDS, R. ELLIOTT, S. J. SCHERER: "Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 19, no. 4, 15 February 2013 (2013-02-15), US, pages 929 - 937, XP055230578, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-2535 * |
| WEIJING SUN, ANUJ PATEL: "Ziv-aflibercept in metastatic colorectal cancer", BIOLOGICS: TARGETS AND THERAPY, pages 13, XP055230180, DOI: 10.2147/BTT.S39360 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201790549A1 (ru) | 2017-07-31 |
| IL250905B (en) | 2019-12-31 |
| AU2015318207A1 (en) | 2017-04-06 |
| ZA201701664B (en) | 2018-05-30 |
| EP3194974A1 (en) | 2017-07-26 |
| US20200129589A1 (en) | 2020-04-30 |
| KR20170055972A (ko) | 2017-05-22 |
| US11439683B2 (en) | 2022-09-13 |
| KR102471057B1 (ko) | 2022-11-28 |
| US20170281725A1 (en) | 2017-10-05 |
| CA2960890A1 (en) | 2016-03-24 |
| US10525104B2 (en) | 2020-01-07 |
| JP2017530372A (ja) | 2017-10-12 |
| CN107076749A (zh) | 2017-08-18 |
| MX382673B (es) | 2025-03-13 |
| EP3194974B1 (en) | 2019-10-23 |
| CN107076749B (zh) | 2020-12-29 |
| MX2017003387A (es) | 2018-01-30 |
| AU2015318207B2 (en) | 2021-11-04 |
| JP6692358B2 (ja) | 2020-05-13 |
| IL250905A0 (en) | 2017-04-30 |
| WO2016044041A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11439683B2 (en) | Anti-angiogenic therapy of metastatic colorectal cancer | |
| JP6055764B2 (ja) | 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー | |
| AU2011281700B2 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer | |
| JP6057718B2 (ja) | ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー | |
| DK2743697T3 (en) | METHODS OF IN VITRO DIAGNOSTICS OF INVASIVE CARCINOMS | |
| KR20140094594A (ko) | 유방암 치료를 위한 베바시주맙 병용 치료에 대한 혈장 바이오마커 | |
| JP2017524127A (ja) | 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法 | |
| KR20120123248A (ko) | 악성 종양의 진단 방법 | |
| Jiang et al. | Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients | |
| HK1202334A1 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
| WO2023190820A1 (ja) | 抗ＣＫ２α抗体又はその断片 | |
| HK1198063A (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
| HK1181459B (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer | |
| HK1184854B (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |